Fig. 4

ROS inhibition restores the impaired HSPC supporting ability of hMSCs and engraftment in xenotransplantation model. (A) A schematic diagram of ROS inhibition in hMSCs and following hMSC-cocultured HSPC transplantation. hMSCs were pretreated with or without NAC for 1 h, and followed by treatment with 5% 3R4F for 72 h. CD34⁺ HSPC were cocultured with 3R4F-treated hMSC. After 3 days, cocultured HSPCs were harvested, enriched via magnetic sorting, and intravenously injected into NSG mice. PB and BM samples were collected at the indicated timepoints for further analyses. (B) HSPC engraftment was evaluated by determining hCD45⁺ cells from PB 8 weeks post transplantation. (C) Repopulation of blood lineage cells (hCD3⁺ T cells, hCD14⁺ monocytes, hCD20⁺ B cells, hCD33⁺ myeloid cells) was analyzed in the PB and BM of NSG mice at 15 weeks post transplantation. n = 3–4 mice/group. The data are presented as the mean ± S.D. of three independent experiments (*p < 0.05; **p < 0.01)